Duvelisib, an oral dual PI3K-δ, γ inhibitor, shows clinical activity in indolent non-Hodgkin lymphoma in a phase 1 study

Keyphrases

• Phase 1 Study 100%
• Duvelisib 100%
• Indolent non-Hodgkin Lymphoma 100%
• Clinical Activity 100%
• Phosphatidylinositol 3-kinase Inhibitor 100%
• Lymphoma Patients 60%
• Hematological Malignancies 40%
• Maximum Tolerated Dose 40%
• Clinical Development 40%
• High Risk 20%
• Acceptable Safety 20%
• Dual Inhibitor 20%
• Adverse Events 20%
• Monotherapy 20%
• Diarrhea 20%
• Phosphoinositide 3-kinase (PI3K) 20%
• Neutropenia 20%
• Relapsed or Refractory 20%
• Sepsis 20%
• Overall Survival 20%
• Dose-limiting Toxicity 20%
• Two-dose 20%
• Median Progression-free Survival 20%
• Dose Escalation 20%
• Safety Profile 20%
• Escherichia Coli 20%
• Median Time 20%
• Dose Level 20%
• Transaminase Elevations 20%
• Duration of Response 20%
• Rash 20%
• Heavily Pretreated 20%
• Clinical Safety 20%
• Acute Respiratory Failure 20%
• Pharmacokinetics-pharmacodynamics (PK-PD) 20%
• Pneumocystis Jirovecii 20%
• Time Response 20%
• Toxicity Grades 20%
• Elevated Liver Enzymes 20%
• Fungal Pneumonia 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Duvelisib 100%
• Nonhodgkin Lymphoma 100%
• Phosphatidylinositol 3 Kinase Inhibitor 100%
• Hematologic Malignancy 40%
• Maximum Tolerated Dose 40%
• Progression Free Survival 20%
• Monotherapy 20%
• Phosphatidylinositol 3 Kinase 20%
• Diarrhea 20%
• Neutropenia 20%
• Adverse Event 20%
• Sepsis 20%
• Overall Survival 20%
• Pharmacodynamics 20%
• Escherichia coli 20%
• Aminotransferase 20%
• Rash 20%
• Hypertransaminasemia 20%
• Acute Respiratory Failure 20%
• Pneumocystis Pneumonia 20%
• Lung Mycosis 20%
• Pharmacokinetics 20%